Categories

Tag: Startups

QUALITY/TECH/POLICY: IFTF meeting on the Global Health Economy

I’m at an IFTF meeting on the Global Health Economy. IFTF has gone a little off into left field on the “health” issue since I left. They’re slowly coming back relating “health” back to the health care system (the stuff that we care about THCB), but the meeting is about personalized health, people opting out of the health care system, “body hacking” and how companies can sell to the health market (which primarily means food!). More later…

TECH: Is Newer Better? It’s a Coin-Toss, by Maggie Mahar

Last week The Annals of Internal Medicine roiled the medical world by publishing a study suggesting that the drug-coated stents produced by companies like Boston Scientific and J&J may not be quite as miraculous as first advertised.Following a two-year study, researchers at the Cedars-Sinai Medical Center in Los Angeles are now suggesting that the “putative superiority” of drug-coated stents "is founded on questionable premises. Or as The Wall Street Journal put it, the clinical trials of drug-coated stents (mostly funded by manufacturers), may “have exaggerated their real-life advantage.

Stents, you may remember, are those tiny metal scaffolds that cardiologists use to prop arteries open after they have been cleared of fatty deposits. Since they were approved in the early 1990s, manufacturers have made a fortune peddling the devices which, they say, can prevent a future heart attack while avoiding riskier and more invasive bypass surgery Today, stents are used in 85% of all coronary interventions in the United States.

Before turning to the new Cedars Sinai study, it should be said that THCB has long harbored doubts as to whether these cunning devices represented the best solution for quite so many patients. Back in 2003, THCB quoted a Stanford study which suggested that, over the long term, patients with multi-vessel disease would achieve better outcomes, at a lower cost, if they opted for the bypass.In 2005 THCB questioned the cost-effectiveness of the new, improved “drug-coated” stents that are designed to prevent the growth of scar tissue inside the artery. Granted, the drug coating has a real advantage: without it, scar tissue can cause the artery to narrow again. And while there is no proof that the coated stent improves survival (the scaring rarely leads to deaths from heart attack), scarring can affect a patient’s quality of life by causing chest pain. And ultimately, he or she may need to have the area opened up again.

Thus, drug-coated stents have become wildly popular, thanks in part to what The Annals of Internal Medicine describes as “aggressive marketing” and the unbridled expectations of patients Wall Street likes them too. At $2300 a pop (vs. a mere $700 for the uncoated, bare-metal variety), the newer stents are far more profitable. Despite the hoopla, nine months ago THCB was once again forced to ask “Are Stents A Waste of Money?” after reading about a study of 826 patients, published in Lancet, which suggested that the drug-coated stents made by J&J and Boston Scientific aren’t cost-effective for all patients and should be restricted to those at highest risk for heart attack.

A second 2005 study, published in The New England Journal of Medicine, added to the uncertainty about the widespread use of stents by reporting that patients suffering minor heart attacks do equally well with drug therapy. "In a study colliding with established practice, recovery from small heart attacks went just as well when doctors gave cardiac drugs time to work as when they favored quick, vessel-clearing procedures,” the NEJM reported. "The surprising Dutch finding raises questions over how to handle the estimated 1.5 million Americans annually who have small heart attacks – the most common kind. Most previous studies support the aggressive, surgical approach. ‘I think both strategies are more or less equivalent. I think it is more a matter of patient preference, doctor preference, logistics and, in the long run, it could be a matter of cost,’ said the Dutch study’s lead researcher, Dr. Robbert J. de Winter of the University Amsterdam."

Against that background, it should come as no surprise that the newest study published in the Annals last week is making hospitals think twice about using coated stents.

Continue reading…

TECH/QUALITY: Buying Guidant still such a great idea?

“We knew, when we did our due diligence, that the [cardiac rhythm management business] of Guidant hadn’t had its last recall,” Chief Executive Jim Tobin said on a conference call with analysts and investors. He said it will take 18 months to 2 years to resolve all of the issues related to the acquisition.

So that’s what the CEO says but the market doesn’t really believe him. As it is Boston Scientific stock is down about 6% on the latest recall of a Guidant device. And that’s before the real story of the future of the Drug Eluting Stent gets out. (More on that arriving at THCB any day now).

TECH: Lost in the memory hole at McKesson

I’ve given my view on RelayHealth before—Nice product but apparently no physician or actual patient demand for it, well not enough that would have sustained a real business that didn’t get unbelievably lucky with its financing in the dotcom days. Now McKesson has bought it to roll it into their health management side that includes the old Access Health and a whole lot of other stuff. If you wnt to read more take a look at this Modern Healthcare article which by its title, McKesson deal gives docs new PHR purveyor, seems to think that RelayHealth is a PHR (stop laughing you at the back).

But what fascinates me is how this stuff happens in Corporate America. In 2000 McKesson purcahsed a company called Medivation. Medivation was tossed into its iMckesson subsidiary and obviously didn’t make it out alive. But the key point is that Medivation’s technology—at last when they bought it—did exactly what RelayHealth’s (the then Healinx) did. Given that neither of them has established much in the way of what you’d recognize as market share or profitability—cue yet more angry emails from Relay Health’s lovely marketing people—I assume McKesson is buying RelayHealth for the technology not to double up on market share. So that means whatever Medivation had has since been lost. And those of us who remember iMckesson may find this line from the story strangely familiar.

In addition to RelayHealth, McKesson’s personal health systems include in-home patient monitoring, web portal technology, triage software and personal emergency response systems. The full suite will include products and services from recently acquired HealthCom Partners, LLC, which provides patient billing solutions designed to simplify and enhance financial interactions between healthcare providers and their patients.

Longtime McKesson observers may not be too surprised —after all I don’t use their products, I just get my cues on their lack of interoperability that from HISTalk. But what I’d like to know is who’s getting fired for buying the same thing twice? For that matter when’s Charlie McCall finally going on trial for screwing up McKesson in the first place? It’s 7 years since that happened? Answers on a post card….

Coda: My best guess is that RelayHealth had c. $40m in funding in rounds C, D & E, so perhaps $45m overall. Now that no one’s feelings can get hurt, and now that the health care Internet is sexy again, I wonder whether their investors got out whole. I assume that we’ll find out in the next 10Q. Any guesses in the comments?

PHYSICIANS/TECH/POLICY/POLITICS: Hard to generate savings when you spend more, eh?

The real medical story of the day is of course Michael Owen’s torn ACL, which leaves the idiot Swede’s decision to take only one fully fit striker plus a kid he won’t play to Germany as dumb as they come. But you lot don’t care about that. Instead let me tell you about my conversation with a consulting firm looking into home monitoring. The people interviewing me, once they’d got past my somewhat cynical notions about how technologies get reimbursed by Medicare and whether private insurers actually give a rats arse about saving money, kept harping on about reimbursement and how to get home monitoring reimbursed.

I made a point that will be all too familiar to THCB readers that if (and it’s not a tiny “if”) remote monitoring of the chronically ill, and all the DM processes that go along with it, is to be done routinely, then someone somewhere will have to give up some of their income to pay for it. In other words, if catching bad things happening to patients before they crash is the end result of home monitoring, there’ll be less money spent on the ones who crash. The optimists among us believe that the amount of that money not spent will exceed the amount spent on the home monitoring and DM, but that’s a subsidiary point. Instead the key issue is that under our current diversified system the people not getting the money for the patients (e.g. doctors and hospitals) who no longer crash are going to be different from the people who get the money for the monitoring (e.g. tech companies and DM service providers).

So if DM programs based around tech use, like the Medicare Health Support pilots or BeWell Mobile’s asthma DM program, are to be successful then they’ll either need additional funding from payors, or redirected funding from payors. When you have a global budget, like the VA, then it may well make sense to bring in this type of program, which is why Health Hero Network is having success with the VA, but struggled to get wide adoption outside it before. But, and you all know this, the VA, Kaiser et al are exceptions.

While leads me to the second part of the equation; how willing is the rest of the system (those doctors and hospitals) to accept less money for any reason—let alone subsidizing the adoption of new technology that will benefit someone else? Well you know the answer to that one, and yesterday came more proof, as apparently the AMA has beaten the Republicans to a bloody pulp and will not have to deal with the draconian fee cuts that were coming their way.

So I remain a skeptic that we’re going to spend more to spend less; I just think that we’re going to (slowly) just spend more.

TECH: The VA and Health IT A Model that Works By Maggie Mahar

VetsDid it ever occur to you that your dog might have better health records than you do? While veterinarians routinely keep computerized records of their four-footed patients’ medications and vaccinations, human health care still relies heavily on pen, paper, phone and those little yellow Post-it notes that all too often come fluttering out of a patient’s file.

While most U.S. industries make superb use of information technology to collect, manage and distribute information, when it comes to healthcare, we lag far behind.  In 2000, 90 percent of physicians in Sweden, 88 percent in the Netherlands, 62 percent in Denmark, 58 percent in the UK, 56 percent in Finland and 48 percent in Germany were using electronic medical records. Six years later, roughly 80 percent of U.S. physicians are still shuffling through manila folders.

Meanwhile only 15 to 20 percent of U.S. hospitals use electronic records–although nearly everyone agrees that computerized medicine is the key to sparing patients the risks and expense of missing records, redundant tests and medication errors.

In “Money-Driven Medicine: The Real Reason Health Care Costs So Much (HarperCollins, May 2006),  I describe, in detail, how healthcare IT could lift quality and, over the long run, help contain costs. Just one example:  if physicians used computers to order medication, we could eliminate two million “adverse drug events” that range from allergic reactions to death.

Concerned about privacy, some patients might opt out. Certainly, legislation will be needed to assure that records will be safe from prying eyes.

But experience shows that where IT is available, most patients like knowing that if they wind up unconscious in an ER, a doctor can open his laptop and find a complete and detailed medical history that includes a list of what drugs they’re taking, pre-exiting conditions, test results, x-rays, prior hospitalizations, notes from various specialists who have examined them.

Dr. David Brailer, the man President Bush appointed as his Health IT czar in 2004, was supposed to usher in an IT revolution in the U.S. But last month Brailer left Washington. Explaining that Brailer was departing for family reasons, the administration  stressed that, despite his brief tenure, he had made “significant progress” toward the president’s goal of giving most Americans electronic records by 2015.

The facts suggest otherwise. Despite much rhetoric, funding Health IT is not among the administration’s priorities.  In 2005 a panel that included Brailer estimated that developing electronic medical records that gather a patient’s history, X-rays, lab results and prescriptions into a single database would require $165 billion in start-up capital –plus $48 billion in annual operating costs.

For fiscal 2007, the White House budget allocated a paltry $169 million to healthcare IT.  By contrast, the UK is spending $11 billion to wire a much smaller system.

The administration hopes the private sector will foot the bill. But hospitals are strapped for cash, and pediatricians earning an average of $150,000 a year are reluctant to spend $44,000 per physician to wire a group practice. Even for a cardiologist earning $500,000, the business case for IT is slim: the financial rewards for avoiding duplicate tests will go to the insurer, not to the doctor. 

Nevertheless, Washington insists that the private sector foot the bill—which brings us to the second hurdle: persuading competing players in a market-driven system to agree on complementary standards. Hospitals and doctors  need electronic records that can talk to each other.

In an interview published in Health Affairs last fall, Brailer acknowledged that “divergent stakeholders’ interests” create “a significant barrier to agreement. . . . It’s the same problem as VHS versus Betamax [videotape], although I think there’s more at stake with health care than with videotapes,” he remarked.

Yet, since Brailer shares the administration’s faith in market-based solutions he  remained committed to trying to coax rival hospitals, doctors, health plans and IT vendors to reach a consensus–even while admitting the real danger that we will wind up with a wired maze of health care providers who still cannot communicate with each other. (Remember when competing U.S. wireless telephone carriers refused to agree on protocols, and we all paid roaming fees?)

As J.D. Kleinke, executive director of Omnidex Institute, a nonprofit health care research and information  technology development organization,   pointed out in a 2005 Health Affairs article titled “Dot-Gov:Market Failure and the Creation of a National Health Information Technology System”:

“The market has refused to coalesce around health care IT standards on its own. The time has come for rational, orderly design, one that will allow us to get on with the real work of improving the health care system with an IT infrastructure that other industries take for granted.”

In April, an article in Modern Healthcare seconded Kleinke’s concern, noting that:

” One of the problems with the administration’s market-based approach is that the market isn’t entirely sold on the idea of a single set of standards for certification of IT systems. The main vendor organization announced its own road map for a national IT system and then grumbled about the government’s pass-fail system for electronic medical records certification, saying letter grades for degrees of success ought to be handed out.”

What is ironic is that the administration’s insistence that the best solutions always spring from market competition ignores one of the most efficient corners of American healthcare: the government’s own fully-wired Veterans’ healthcare system –a system that Fortune magazine recently called “the most cost- effective health system in the land.”  (May 15, 2006)

The VA’s IT revolution began in 1994, when a new leader, Dr, Kenneth Kizer, ordered a gut-renovation.  When I visited a Veteran’s hospital in Vermont last spring, I was impressed by the results.

When a physician prescribes a new medicine, he calls up the patient’s chart on his laptop and taps in the order; the computer then checks the drug against others the patient is taking, and warns if there might be an adverse reaction.

IT helps co-ordinate care. At many hospitals, if five specialists are called in to consult on a patient, they may not consult with each other. At the VA, they are each making notes on the same electronic chart, creating what is, in effect, an ongoing dialogue.

When Hurricane Katrina forced the relocation from New Orleans to Houston of hundreds of Veterans Affairs hospital patients, electronic medical records enabled doctors and nurses to treat the sick and injured “without skipping a beat” according to the Washington Post .

The VA also uses its database of how thousands of patients have responded to various treatments to make the head-to-head comparisons of risks and benefits that drug-makers loathe. Relying on that data, the VA , like the Mayo Clinic and Kaisier Pemanentne (which also has an impressive IT system),  curtailed its use of Vioxx two years before  Merck took the drug off the market.

How could the VA afford IT?  The answer is simple: VA hospitals aren’t competing with anyone. When allocating resources, Kizer was making medical decisions, not marketing decisions. By contrast, in the fiercely competitive private sector, even not-for-profit hospitals must ask themselves: Which is more likely to bring in well-insured customers, a new heart pavilion with a waterfall, or IT that won’t pay off for years? Thus, many communities have more heart centers than they need—all overflowing with paper.

The VA has not achieved medical Utopia. Lapses at individual hospitals still set television cameras whirring, and those stories can overshadow the larger tale of systemic reform.

But the VA’s triumphs in “Creating a Culture of Quality” have grabbed headlines in medical journals where studies show the VA matching private-sector health care both in term so quality and costs. (See The New England Journal of Medicine ("Effect of the Transformation of the Veterans Affarirs Health Care System on the Quality of Care, May 29, 2003)The Annals of Internal Medicine ("Diabetes Care Quality in the Veterans Affairs Health Care System and Commercial Managed Care: The TRIAD Study," August 17, 2004) and the American Journal of Managed Care ("The Veterans Health Administration: Quality, Value, Accountability, and Information as Transforming Strategies for Patient-Centered Care," 2004,10; part2). Mainstream media have also recognized the VA’s achievements (see Washington Monthly ("The Best Care Anywhere," January/February 2005) The Washington Post ("Revamped Veterans Health Care Now a Model," August 22, 2005).

The VA has been doing more with less. By 2005 the number of patients the VA was treating had doubled in ten years. Meanwhile a more efficient system had cut costs by half.

Washington’s reaction to the VA’s success?  Starve the beast.

As Bloomberg News has  pointed out , (August 18, 2005) as the Veterans system improved, it has  attracted more and more veterans who wanted care. “Greater-than-expected demand for services from soldiers returning from Iraq and Afghanistan" also added to demand  But, Congress have refused to fund the VA system "to keep pace with health care inflation and rising enrollments."

In 2005, Bloomberg reported out that "in the seven years after the Veterans Healthcare Reform Act was enacted in 1996, enrollment grew 141 percent to 7 million while funding increased 60 percent.  The VA’s healthcare system may be more efficient than the  private sector–but it can’t be that much more efficient. It needs funding.

Since 2005, the VA has gotten some additional funds– but not enough. Too often, Vets face long waits for care. And as of 2003, the VA no longer offers healthcare to all vets. Only those who earn less than $25,000 a year, and/or those whose condition is related to their medical service qualify,  leaving roughly 1.7 million Vets uninsured. Many served in Vietnam, the Gulf War, Afghanistan or Iraq. Most are employed, but in many cases, either their employer doesn’t offer health insurance or they can’t afford it. (With annual  premiums averaging  $4000 for an individual, and well over $10,000 for a family, it’s easy to see how a Vet earning $25,000—before taxes—has a hard time paying for health insurance.,.)

Perhaps Washington needs to re-think its agenda.  Fund the one part of our health care system that works, and look to the VA as a model to ensure that medical priorities— rather than the market’s priorities—dictate how to bring U.S. healthcare into the 21st century.

How can other healthcare providers follow the VA model?

Ken Kizer might have a solution. The man who transformed the VA is now CEO of Medsphere Systems, a company that is adapting the VA’s software (VisTa) for other doctors and hospitals.  The software itself is free— anyone can download it online. But you still need to install VisTa, adapt it, and learn how to use it. Medsphere offers those services plus 24-hour support to customers like Midland Memorial Hospital in Texas.  Because Midland didn’t have to pay licensing fees for the software, it says it is spending only $7.1 million– less than half the total cost of commercial software.

The key is that, in contrast to the proprietary software that many companies sell, the VA software is “open source” which means that it’s available at no or minimal cost, and allows different IT systems to operate compatibly.  Because anyone can download it, the software is not controlled by Medsphere or any single company. Instead, a community of users can work to improve the code simultaneously, sharing ideas, and speeding development.

Cynics suggest that corporate lobbyists who hope to turn a neat profit on proprietary software will block open source Health IT.  And money is still an obstacle: hospitals and doctors will need subsidies.

But if Congress has the will, the VA has shown the way.

TECH: No I’m Not Really ChangingMy View About IT in Healthcare, But …By The Industry Veteran

So maybe IT can have some marginal role after all in addressing health care costs and quality.  The key word is “marginal” and the point of influence is not necessarily where the techie devotees think it will be.  I still believe the focus upon IT in the provider segment is mainly a dodge, but here’s some information that has me at least conceding the “marginal” effect.

The Big Pharma companies, in their current, manic effort to devise methods of reducing SG&A expenses by slashing their sales forces, are currently contemplating vastly expanded roles for websites and other IT venues to deliver their commercials in lieu of in-person reps.

Some of the communication strategies under consideration are highly ingenious.  They involve conferring CME credits on physicians as well as other inducements, some pecuniary and others hedonistic.  Most of the schemes involve simplified, e-versions for physicians to obtain samples, patient information materials and invitations to offsite sessions.  A number of the tactical plans involve gifting physicians with handheld devices that can also digitize charting even as they deliver commercially slanted education/information.

I have my doubts about whether any of this rep-in-the-hand stuff will reduce costs for payers or improve the quality of delivery. Certainly the determining factor over whether its gets deployed in the first place consists of the extent to which it improves the margins of pharma companies and the pocket cash for physicians.  If anyone thinks that an improved take home for these two groups will, for instance, lower drug prices, then he’s also probably persuaded that the US invaded Iraq to remove WMDs and replace a brutal dictator with democracy. I have my doubts about the value of spending much time trying to change the thinking of such believers.   

TECH: If he beeps, he’s clean Bob By John Irvine

“It’s really no different than a tamperproof passport you can carry all
the time,” Applied Digital CEO Scott Silverman, attempting to explain
why  his company’s proposal to use surgically
implanted RFID microchips to help keep tabs on immigrants is really not as
frightening as it sounds.  Silverman says Applied Digital subsidiary VeriChip wants to work
with the Department of Homeland Security to develop a guest worker program
using the technology. 

The VeriChip was approved by the Food and Drug
Administration for human use in 2002 but has not seen widespread usage in the
healthcare industry.  By way of contrast, the company claims the VeriChip has been implanted in about 30 million animals.

In an interview on Fox News several weeks ago, Silverman said
several congressional leaders have expressed interest in the idea of using the
technology for border control.

FOOTNOTED: It turns out that the Department of Homeland
Security may not be all that keen on the idea, anyway. A DHS sub-committee
released a report Wednesday which concludes that using RFID to track people is
probably not a good idea in the first place. The report, titled “The Use of
RFID for Human Identification
” by the Emerging Applications and Techology
Subcommittee, warns that potential privacy problems make the technology something the government should avoid for now. That conclusion
drew protests from the Information Technology Association of America (ITAA) ,
an industry trade group. While conceding
that privacy issues exist, a spokesman for the group blamed the negative review
on “insufficient industry expertise” on the panel…

Amazing the things you learn if you read magazines
with exciting titles like Government Technology. I’m hooked.

 

CONSUMERS/HEALTH PLANS/HOSPITALS/TECH: Consumer comparison tools, not exactly wowing the world as yet

There’s a new report from CHCF, written by Katy Hendrickson at Forrester, it’s called  (pdf) Health Care Cost Comparison Tools: A market under construction. I’ve read it and it does suggest that something is slowly happening in the Submio/Health Grades world, but that it’s mostly about a few plans trying to steer consumers around based on quality….we are a long, long way from price transparency. Stll def worth a read if you’re all interested in consumerism, transparency or health care cost and quality. And apparently some of you are

There’s also a companion report out called Consumers in Health Care: Creating Decision-Support Tools That Work . I haven’t read that one yet. Comments please from anyone who does.

 

assetto corsa mods